Copyright Reports & Markets. All rights reserved.

Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Market Insights and Forecast to 2027

Request for Sample of this report
Buy now

1 Study Coverage

  • 1.1 PARP (Poly ADP-Ribose Polymerase) Inhibitor Product Introduction
  • 1.2 Market by Type
    • 1.2.1 Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Market Size Growth Rate by Type
    • 1.4.2 Lynparza
    • 1.4.3 Zejula
    • 1.2.4 Rubraca
    • 1.2.5 Talzenna
    • 1.2.6 Other
  • 1.3 Market by Application
    • 1.3.1 Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Market Size Growth Rate by Application
    • 1.3.2 Ovarian Cancer
    • 1.3.3 Breast Cancer
    • 1.3.4 Other
  • 1.4 Study Objectives
  • 1.5 Years Considered

2 Executive Summary

  • 2.1 Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales Estimates and Forecasts 2016-2027
  • 2.2 Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Revenue Estimates and Forecasts 2016-2027
  • 2.3 Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Revenue by Region: 2016 VS 2021 VS 2027
  • 2.4 Global Top PARP (Poly ADP-Ribose Polymerase) Inhibitor Regions by Sales
    • 2.4.1 Global Top PARP (Poly ADP-Ribose Polymerase) Inhibitor Regions by Sales (2016-2021)
    • 2.4.2 Global Top PARP (Poly ADP-Ribose Polymerase) Inhibitor Regions by Sales (2022-2027)
  • 2.5 Global Top PARP (Poly ADP-Ribose Polymerase) Inhibitor Regions by Revenue
    • 2.5.1 Global Top PARP (Poly ADP-Ribose Polymerase) Inhibitor Regions by Revenue (2016-2021)
    • 2.5.2 Global Top PARP (Poly ADP-Ribose Polymerase) Inhibitor Regions by Revenue (2022-2027)
  • 2.6 North America
  • 2.7 Europe
  • 2.8 Asia-Pacific
  • 2.9 Latin America
  • 2.10 Middle East & Africa

3 Competition by Manufacturers

  • 3.1 Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales by Manufacturers
    • 3.1.1 Global Top PARP (Poly ADP-Ribose Polymerase) Inhibitor Manufacturers by Sales (2016-2021)
    • 3.1.2 Global Top PARP (Poly ADP-Ribose Polymerase) Inhibitor Manufacturers Market Share by Sales (2016-2021)
    • 3.1.3 Global Top 10 and Top 5 Companies by PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales in 2020
  • 3.2 Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Revenue by Manufacturers
    • 3.2.1 Global Top PARP (Poly ADP-Ribose Polymerase) Inhibitor Manufacturers by Revenue (2016-2021)
    • 3.2.2 Global Top PARP (Poly ADP-Ribose Polymerase) Inhibitor Manufacturers Market Share by Revenue (2016-2021)
    • 3.2.3 Global Top 10 and Top 5 Companies by PARP (Poly ADP-Ribose Polymerase) Inhibitor Revenue in 2020
  • 3.3 Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales Price by Manufacturers
  • 3.4 Analysis of Competitive Landscape
    • 3.4.1 Manufacturers Market Concentration Ratio (CR5 and HHI)
    • 3.4.2 Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
    • 3.4.3 Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Manufacturers Geographical Distribution
  • 3.5 Mergers & Acquisitions, Expansion Plans

4 Market Size by Type

  • 4.1 Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales by Type
    • 4.1.1 Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Historical Sales by Type (2016-2021)
    • 4.1.2 Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Forecasted Sales by Type (2022-2027)
    • 4.1.3 Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales Market Share by Type (2016-2027)
  • 4.2 Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Revenue by Type
    • 4.2.1 Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Historical Revenue by Type (2016-2021)
    • 4.2.2 Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Forecasted Revenue by Type (2022-2027)
    • 4.2.3 Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Revenue Market Share by Type (2016-2027)
  • 4.3 Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Price by Type
    • 4.3.1 Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Price by Type (2016-2021)
    • 4.3.2 Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Price Forecast by Type (2022-2027)

5 Market Size by Application

  • 5.1 Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales by Application
    • 5.1.1 Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Historical Sales by Application (2016-2021)
    • 5.1.2 Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Forecasted Sales by Application (2022-2027)
    • 5.1.3 Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales Market Share by Application (2016-2027)
  • 5.2 Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Revenue by Application
    • 5.2.1 Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Historical Revenue by Application (2016-2021)
    • 5.2.2 Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Forecasted Revenue by Application (2022-2027)
    • 5.2.3 Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Revenue Market Share by Application (2016-2027)
  • 5.3 Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Price by Application
    • 5.3.1 Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Price by Application (2016-2021)
    • 5.3.2 Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Price Forecast by Application (2022-2027)

6 North America

  • 6.1 North America PARP (Poly ADP-Ribose Polymerase) Inhibitor Market Size by Type
    • 6.1.1 North America PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales by Type (2016-2027)
    • 6.1.2 North America PARP (Poly ADP-Ribose Polymerase) Inhibitor Revenue by Type (2016-2027)
  • 6.2 North America PARP (Poly ADP-Ribose Polymerase) Inhibitor Market Size by Application
    • 6.2.1 North America PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales by Application (2016-2027)
    • 6.2.2 North America PARP (Poly ADP-Ribose Polymerase) Inhibitor Revenue by Application (2016-2027)
  • 6.3 North America PARP (Poly ADP-Ribose Polymerase) Inhibitor Market Size by Country
    • 6.3.1 North America PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales by Country (2016-2027)
    • 6.3.2 North America PARP (Poly ADP-Ribose Polymerase) Inhibitor Revenue by Country (2016-2027)
    • 6.3.3 U.S.
    • 6.3.4 Canada

7 Europe

  • 7.1 Europe PARP (Poly ADP-Ribose Polymerase) Inhibitor Market Size by Type
    • 7.1.1 Europe PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales by Type (2017-2027)
    • 7.1.2 Europe PARP (Poly ADP-Ribose Polymerase) Inhibitor Revenue by Type (2017-2027)
  • 7.2 Europe PARP (Poly ADP-Ribose Polymerase) Inhibitor Market Size by Application
    • 7.2.1 Europe PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales by Application (2017-2027)
    • 7.2.2 Europe PARP (Poly ADP-Ribose Polymerase) Inhibitor Revenue by Application (2017-2027)
  • 7.3 Europe PARP (Poly ADP-Ribose Polymerase) Inhibitor Market Size by Country
    • 7.3.1 Europe PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales by Country (2017-2027)
    • 7.3.2 Europe PARP (Poly ADP-Ribose Polymerase) Inhibitor Revenue by Country (2017-2027)
    • 7.3.3 Germany
    • 7.3.4 France
    • 7.3.5 U.K.
    • 7.3.6 Italy
    • 7.3.7 Russia

8 Asia Pacific

  • 8.1 Asia Pacific PARP (Poly ADP-Ribose Polymerase) Inhibitor Market Size by Type
    • 8.1.1 Asia Pacific PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales by Type (2018-2027)
    • 8.1.2 Asia Pacific PARP (Poly ADP-Ribose Polymerase) Inhibitor Revenue by Type (2018-2027)
  • 8.2 Asia Pacific PARP (Poly ADP-Ribose Polymerase) Inhibitor Market Size by Application
    • 8.2.1 Asia Pacific PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales by Application (2018-2027)
    • 8.2.2 Asia Pacific PARP (Poly ADP-Ribose Polymerase) Inhibitor Revenue by Application (2018-2027)
  • 8.3 Asia Pacific PARP (Poly ADP-Ribose Polymerase) Inhibitor Market Size by Region
    • 8.3.1 Asia Pacific PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales by Region (2018-2027)
    • 8.3.2 Asia Pacific PARP (Poly ADP-Ribose Polymerase) Inhibitor Revenue by Region (2018-2027)
    • 8.3.3 China
    • 8.3.4 Japan
    • 8.3.5 South Korea
    • 8.3.6 India
    • 8.3.7 Australia
    • 8.3.8 Taiwan
    • 8.3.9 Indonesia
    • 8.3.10 Thailand
    • 8.3.11 Malaysia
    • 8.3.12 Philippines

9 Latin America

  • 9.1 Latin America PARP (Poly ADP-Ribose Polymerase) Inhibitor Market Size by Type
    • 9.1.1 Latin America PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales by Type (2019-2027)
    • 9.1.2 Latin America PARP (Poly ADP-Ribose Polymerase) Inhibitor Revenue by Type (2019-2027)
  • 9.2 Latin America PARP (Poly ADP-Ribose Polymerase) Inhibitor Market Size by Application
    • 9.2.1 Latin America PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales by Application (2019-2027)
    • 9.2.2 Latin America PARP (Poly ADP-Ribose Polymerase) Inhibitor Revenue by Application (2019-2027)
  • 9.3 Latin America PARP (Poly ADP-Ribose Polymerase) Inhibitor Market Size by Country
    • 9.3.1 Latin America PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales by Country (2019-2027)
    • 9.3.2 Latin America PARP (Poly ADP-Ribose Polymerase) Inhibitor Revenue by Country (2019-2027)
    • 9.3.3 Mexico
    • 9.3.4 Brazil
    • 9.3.5 Argentina

6 Middle East and Africa

  • 6.1 Middle East and Africa PARP (Poly ADP-Ribose Polymerase) Inhibitor Market Size by Type
    • 6.1.1 Middle East and Africa PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales by Type (2016-2027)
    • 6.1.2 Middle East and Africa PARP (Poly ADP-Ribose Polymerase) Inhibitor Revenue by Type (2016-2027)
  • 6.2 Middle East and Africa PARP (Poly ADP-Ribose Polymerase) Inhibitor Market Size by Application
    • 6.2.1 Middle East and Africa PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales by Application (2016-2027)
    • 6.2.2 Middle East and Africa PARP (Poly ADP-Ribose Polymerase) Inhibitor Revenue by Application (2016-2027)
  • 6.3 Middle East and Africa PARP (Poly ADP-Ribose Polymerase) Inhibitor Market Size by Country
    • 6.3.1 Middle East and Africa PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales by Country (2016-2027)
    • 6.3.2 Middle East and Africa PARP (Poly ADP-Ribose Polymerase) Inhibitor Revenue by Country (2016-2027)
    • 6.3.3 Turkey
    • 6.3.4 Saudi Arabia
    • 6.3.5 UAE

11 Company Profiles

  • 11.1 AstraZeneca
    • 11.1.1 AstraZeneca Corporation Information
    • 11.1.2 AstraZeneca Overview
    • 11.1.3 AstraZeneca PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales, Price, Revenue and Gross Margin (2016-2021)
    • 11.1.4 AstraZeneca PARP (Poly ADP-Ribose Polymerase) Inhibitor Product Description
    • 11.1.5 AstraZeneca Related Developments
  • 11.2 Tesaro
    • 11.2.1 Tesaro Corporation Information
    • 11.2.2 Tesaro Overview
    • 11.2.3 Tesaro PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales, Price, Revenue and Gross Margin (2016-2021)
    • 11.2.4 Tesaro PARP (Poly ADP-Ribose Polymerase) Inhibitor Product Description
    • 11.2.5 Tesaro Related Developments
  • 11.3 Merck & Co
    • 11.3.1 Merck & Co Corporation Information
    • 11.3.2 Merck & Co Overview
    • 11.3.3 Merck & Co PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales, Price, Revenue and Gross Margin (2016-2021)
    • 11.3.4 Merck & Co PARP (Poly ADP-Ribose Polymerase) Inhibitor Product Description
    • 11.3.5 Merck & Co Related Developments
  • 11.4 Clovis Oncology
    • 11.4.1 Clovis Oncology Corporation Information
    • 11.4.2 Clovis Oncology Overview
    • 11.4.3 Clovis Oncology PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales, Price, Revenue and Gross Margin (2016-2021)
    • 11.4.4 Clovis Oncology PARP (Poly ADP-Ribose Polymerase) Inhibitor Product Description
    • 11.4.5 Clovis Oncology Related Developments
  • 11.5 Pfizer
    • 11.5.1 Pfizer Corporation Information
    • 11.5.2 Pfizer Overview
    • 11.5.3 Pfizer PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales, Price, Revenue and Gross Margin (2016-2021)
    • 11.5.4 Pfizer PARP (Poly ADP-Ribose Polymerase) Inhibitor Product Description
    • 11.5.5 Pfizer Related Developments
  • 11.1 AstraZeneca
    • 11.1.1 AstraZeneca Corporation Information
    • 11.1.2 AstraZeneca Overview
    • 11.1.3 AstraZeneca PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales, Price, Revenue and Gross Margin (2016-2021)
    • 11.1.4 AstraZeneca PARP (Poly ADP-Ribose Polymerase) Inhibitor Product Description
    • 11.1.5 AstraZeneca Related Developments

12 Value Chain and Sales Channels Analysis

  • 12.1 PARP (Poly ADP-Ribose Polymerase) Inhibitor Value Chain Analysis
  • 12.2 PARP (Poly ADP-Ribose Polymerase) Inhibitor Key Raw Materials
    • 12.2.1 Key Raw Materials
    • 12.2.2 Raw Materials Key Suppliers
  • 12.3 PARP (Poly ADP-Ribose Polymerase) Inhibitor Production Mode & Process
  • 12.4 PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales and Marketing
    • 12.4.1 PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales Channels
    • 12.4.2 PARP (Poly ADP-Ribose Polymerase) Inhibitor Distributors
  • 12.5 PARP (Poly ADP-Ribose Polymerase) Inhibitor Customers

13 Market Drivers, Opportunities, Challenges and Risks Factors Analysis

  • 13.1 PARP (Poly ADP-Ribose Polymerase) Inhibitor Industry Trends
  • 13.2 PARP (Poly ADP-Ribose Polymerase) Inhibitor Market Drivers
  • 13.3 PARP (Poly ADP-Ribose Polymerase) Inhibitor Market Challenges
  • 13.4 PARP (Poly ADP-Ribose Polymerase) Inhibitor Market Restraints

14 Key Findings in The Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Study

    15 Appendix

    • 15.1 Research Methodology
      • 15.1.1 Methodology/Research Approach
      • 15.1.2 Data Source
    • 15.2 Author Details

    PARP (Poly ADP-Ribose Polymerase) Inhibitor market is segmented by Type, and by Application. Players, stakeholders, and other participants in the global PARP (Poly ADP-Ribose Polymerase) Inhibitor market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on sales, revenue and forecast by Type and by Application for the period 2016-2027.

    Segment by Type
    Lynparza
    Zejula
    Rubraca
    Talzenna
    Other

    Segment by Application
    Ovarian Cancer
    Breast Cancer
    Other

    By Company
    AstraZeneca
    Tesaro
    Merck & Co
    Clovis Oncology
    Pfizer

    By Region
    North America
    U.S.
    Canada
    Europe
    Germany
    France
    U.K.
    Italy
    Russia
    Asia-Pacific
    China
    Japan
    South Korea
    India
    Australia
    Taiwan
    Indonesia
    Thailand
    Malaysia
    Philippines
    Vietnam
    Latin America
    Mexico
    Brazil
    Argentina
    Middle East & Africa
    Turkey
    Saudi Arabia

    Buy now